Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:FOLD
Previous Symbol
CUSIP03152W10
Phone609-662-2000
Debt
Debt-to-Equity Ratio0.78
Current Ratio9.12
Quick Ratio9.03
Price-To-Earnings
Trailing P/E Ratio-3.63
Forward P/E Ratio-8.66
P/E GrowthN/A
Sales & Book Value
Annual Sales$36.93 million
Price / Sales54.13
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.12 per share
Price / Book4.98
Profitability
EPS (Most Recent Fiscal Year)($2.92)
Net Income$-284,000,000.00
Net Margins-463.82%
Return on Equity-52.03%
Return on Assets-30.40%
Miscellaneous
Employees325
Outstanding Shares189,290,000
Market Cap$1.88 billion
OptionableOptionable
Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions
What is Amicus Therapeutics' stock symbol?
Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."
How were Amicus Therapeutics' earnings last quarter?
Amicus Therapeutics, Inc. (NASDAQ:FOLD) released its earnings results on Monday, November, 5th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.27) by $0.04. The biopharmaceutical company had revenue of $20.60 million for the quarter, compared to the consensus estimate of $23.56 million. Amicus Therapeutics had a negative net margin of 463.82% and a negative return on equity of 52.03%. Amicus Therapeutics's revenue for the quarter was up 89.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.41) EPS. View Amicus Therapeutics' Earnings History.
When is Amicus Therapeutics' next earnings date?
What guidance has Amicus Therapeutics issued on next quarter's earnings?
Amicus Therapeutics updated its FY 2018 earnings guidance on Monday, November, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $80-90 million, compared to the consensus revenue estimate of $89.85 million.
What price target have analysts set for FOLD?
5 Wall Street analysts have issued 12 month target prices for Amicus Therapeutics' stock. Their forecasts range from $12.00 to $31.00. On average, they expect Amicus Therapeutics' stock price to reach $20.40 in the next twelve months. This suggests a possible upside of 93.2% from the stock's current price. View Analyst Price Targets for Amicus Therapeutics.
What is the consensus analysts' recommendation for Amicus Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amicus Therapeutics.
Has Amicus Therapeutics been receiving favorable news coverage?
News headlines about FOLD stock have been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amicus Therapeutics earned a media sentiment score of 1.1 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days.
Are investors shorting Amicus Therapeutics?
Amicus Therapeutics saw a increase in short interest in November. As of November 30th, there was short interest totalling 27,021,118 shares, an increase of 0.5% from the November 15th total of 26,878,977 shares. Based on an average trading volume of 1,925,575 shares, the days-to-cover ratio is currently 14.0 days. Approximately 14.6% of the shares of the stock are short sold. View Amicus Therapeutics' Current Options Chain.
Who are some of Amicus Therapeutics' key competitors?
Some companies that are related to Amicus Therapeutics include Ionis Pharmaceuticals (IONS), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), Alkermes (ALKS), Catalent (CTLT), Amneal Pharmaceuticals (AMRX), GALAPAGOS NV/S (GLPG), SAGE Therapeutics (SAGE), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), Loxo Oncology (LOXO), TESARO (TSRO), Taro Pharmaceutical Industries (TARO) and GW Pharmaceuticals PLC- (GWPH).
Who are Amicus Therapeutics' key executives?
Amicus Therapeutics' management team includes the folowing people:
- Mr. John F. Crowley, Chairman & CEO (Age 51)
- Mr. Bradley L. Campbell, Pres, COO & Director (Age 42)
- Mr. William D. Baird III, Chief Financial Officer (Age 46)
- Ms. Ellen S. Rosenberg, Gen. Counsel & Corp. Sec. (Age 55)
- Dr. Jay A. Barth, Chief Medical Officer (Age 54)
Who are Amicus Therapeutics' major shareholders?
Amicus Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (10.93%), Vanguard Group Inc. (8.88%), BlackRock Inc. (8.65%), FMR LLC (7.11%), Jennison Associates LLC (5.32%) and Janus Henderson Group PLC (4.65%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.
Which major investors are selling Amicus Therapeutics stock?
FOLD stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Franklin Resources Inc., Allianz Asset Management GmbH, Morgan Stanley, Wexford Capital LP, Russell Investments Group Ltd., AQR Capital Management LLC and Jennison Associates LLC. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Margaret G Mcglynn, Michael Raab and William D Baird III. View Insider Buying and Selling for Amicus Therapeutics.
Which major investors are buying Amicus Therapeutics stock?
FOLD stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Point72 Asset Management L.P., Rothschild & Co. Asset Management US Inc., Marshall Wace LLP, Perceptive Advisors LLC, AXA, Janus Henderson Group PLC and Sphera Funds Management LTD.. Company insiders that have bought Amicus Therapeutics stock in the last two years include John F Crowley, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.
How do I buy shares of Amicus Therapeutics?
Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amicus Therapeutics' stock price today?
One share of FOLD stock can currently be purchased for approximately $10.56.
How big of a company is Amicus Therapeutics?
Amicus Therapeutics has a market capitalization of $1.88 billion and generates $36.93 million in revenue each year. The biopharmaceutical company earns $-284,000,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Amicus Therapeutics employs 325 workers across the globe.
What is Amicus Therapeutics' official website?
How can I contact Amicus Therapeutics?
Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]
MarketBeat Community Rating for Amicus Therapeutics (NASDAQ FOLD)
MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe FOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
